Smoking Clinical Trial
Official title:
Palatability of Experimental Cigarettes
NCT number | NCT01568905 |
Other study ID # | 1012M94314 |
Secondary ID | |
Status | Completed |
Phase | N/A |
First received | |
Last updated | |
Start date | February 2011 |
Est. completion date | March 2012 |
Verified date | October 2019 |
Source | University of Minnesota |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
Smoking remains a leading cause of preventable disease and premature death worldwide. Approximately 1 out of every 5 deaths is associated with cigarette smoking, and roughly half of all daily smokers will die prematurely from tobacco-related illness. Reducing the nicotine in cigarettes to the point that they are rendered non-addictive can potentially be an effective public policy measure that can significantly reduce tobacco-related mortality and morbidity by decreasing the initiation of smoking and promoting cessation. The Family Smoking Prevention and Tobacco Control Act (FSPTCA) enables the FDA to establish tobacco product standards including placing limits on the allowable nicotine content of cigarettes. Currently, no reduced nicotine cigarettes are available that will allow studying the feasibility of this policy measure. The National Institute on Drug Abuse has contracted with Research Triangle Institute to assist in the development of cigarettes with varying nicotine content that can be made available to researchers. They have established a contract that will result in the manufacture of 9 million cigarettes to be distributed to the research community. Prior to full production, the palatability and nicotine intake of these cigarettes in smokers must be determined.
Status | Completed |
Enrollment | 36 |
Est. completion date | March 2012 |
Est. primary completion date | March 2012 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 18 Years to 64 Years |
Eligibility |
Inclusion Criteria: - 18-64 years old - Regular smokers (10+ cigarettes per day and has done so for the last year) - Inhaling when smoking - Carbon monoxide (CO) > 8 ppm Exclusion Criteria: - In the past year, suffered from any cardiovascular disease such as: heart disease, heart attack, stroke or angina, any respiratory diseases such as chronic bronchitis or chronic obstructive pulmonary disease (COPD), any type of cancer - Currently suffering from Bipolar Disorder, General Anxiety Disorder, Schizophrenia, or a major depressive episode - Taken any of the following drugs more than twice per week during the past month: antidepressants, anti-anxiety medications. - Consumed more than 15 alcoholic drinks per week for the past month - Pregnant, trying to become pregnant, or lactating (assessed by self-report) - In the past 3 months, used nicotine replacement products (like the patch, gum, or inhaler), or the medications bupropion varenicline - Currently trying or planning to reduce or quit tobacco use in the next 30 days - Used other forms of tobacco 10 or more days in the past 30 days |
Country | Name | City | State |
---|---|---|---|
United States | University of Minnesota | Minneapolis | Minnesota |
Lead Sponsor | Collaborator |
---|---|
University of Minnesota |
United States,
Hatsukami DK, Heishman SJ, Vogel RI, Denlinger RL, Roper-Batker AN, Mackowick KM, Jensen J, Murphy SE, Thomas BF, Donny E. Dose-response effects of spectrum research cigarettes. Nicotine Tob Res. 2013 Jun;15(6):1113-21. doi: 10.1093/ntr/nts247. Epub 2012 — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in UrineTotal Nicotine Equivalent (TNE) Between Baseline and Week 1 | Two urine TNE levels are taken, one at baseline and one at week 1, to assess TNE levels for nicotine exposure. TNE is the sum of nicotine, cotinine, trans 3'-hydroxycotinine and their respective glucuronide conjugates. Values reported in nmols/ml. | Second Visit (Week 1) minus Baseline (Day 1) | |
Secondary | Responses on Modified Cigarette Evaluation Scale | Modified Cigarette Evaluation Scale [CES] is a 100 mm visual analog scale (0=not at all or very little nicotine; 100=extremely or high in nicotine) of 20 questions assessing different dimensions of responses to usual brand cigarettes (e.g., psychological reward, satisfaction and aversiveness) and includes additional 5 point likert-type questions (definitely agree to definitely disagree) on perceptions of satisfaction and willingness to use the product. Results satisfaction subscale. | Baseline usual brand cigarettes (Day 1) compared to when using study cigarettes (Week 1) | |
Secondary | Change From Baseline of Perceived Health Risk Scale Response to Test Cigarettes | Questionnaire: Perceived Health Risk Scale asks subjects to rate their perception of health risks for lung cancer for the study product to which they have been randomly assigned. This is a 100 mm visual analog scale; 0=very low risk of disease, 100=very high risk of disease. | Baseline (Day 1) Compared to Second Visit (Week 1) | |
Secondary | Comparison of Number of Cigarettes Smoked | Subjects were given a daily diary to collect the number of study and/or conventional cigarettes they have smoked each day. Cigarettes smoked (both usual brand and experimental) in a given week were summed over the first 7 reported days. If the number of cigarettes smoked was missing for 1 day, the average of the other days in that week was used in its place and reported as total number of cigarettes per week. | 1 week |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT03999411 -
Smartphone Intervention for Smoking Cessation and Improving Adherence to Treatment Among HIV Patients
|
Phase 4 | |
Completed |
NCT03931772 -
Online Automated Self-Hypnosis Program
|
N/A | |
Completed |
NCT02649556 -
A 26-week Extension of the ZRHR-ERS-09-US Study Evaluating Biological and Functional Changes in Healthy Smokers After Switching to THS 2.2
|
N/A | |
Completed |
NCT03901066 -
Smoking Dependence and Periodontitis
|
||
Recruiting |
NCT05846841 -
Personalized Tobacco Treatment in Primary Care (MOTIVATE)
|
N/A | |
Completed |
NCT03170752 -
Implementing and Testing a Cardiovascular Assessment Screening Program (CASP)
|
N/A | |
Completed |
NCT03305978 -
Pulmonary Nodule Detection: Comparison of an Ultra Low Dose vs Standard Scan.
|
N/A | |
Completed |
NCT00000437 -
Tobacco Dependence in Alcoholism Treatment (Nicotine Patch/Naltrexone)
|
Phase 4 | |
Completed |
NCT06105424 -
BRP1602: Evaluation of Technical and Logistical Feasibility to Measure Lung Permeability
|
N/A | |
Active, not recruiting |
NCT02752022 -
Monitoring the Transition From Smoking to E-cigarettes
|
||
Completed |
NCT03206619 -
A Health Recommeder System to Tailor Message Preferences in a Smoking Cessation Programme
|
||
Completed |
NCT04340830 -
The Effect of Smoking on Dimensional Changes of Free Gingival Graft Around Dental Implants
|
N/A | |
Completed |
NCT02912000 -
TEACH: Technology Evaluation to Address Child Health
|
N/A | |
Completed |
NCT02901171 -
The Contribution of a Smartphone Application to Acceptance and Commitment Therapy Group Treatment for Smoking Cessation
|
N/A | |
Completed |
NCT02949648 -
Electronic Cigarette Use and Quitting in Youth
|
N/A | |
Completed |
NCT02945371 -
Tailored Inhibitory Control Training to Reverse EA-linked Deficits in Mid-life
|
N/A | |
Completed |
NCT02246114 -
Self-Monitoring of Carbon Monoxide to Enhance Reproductive Outcomes in Women
|
N/A | |
Completed |
NCT03448900 -
Intervention Study for Smoking Cessation in Spanish College Students
|
N/A | |
Completed |
NCT01898507 -
Nicotine Metabolism and Low Nicotine Cigarettes
|
N/A | |
Completed |
NCT01954407 -
Young Adults' Responses to Anti-smoking Messages
|
N/A |